In a statement, Prime Minister Keir Starmer said the "significant investment" had been "made possible by the pharmaceutical ...

Italian pharma group Chiesi has bolstered its rare disease business with an agreement to buy US biopharma KalVista Pharma and ...

The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur, saying this could ...

Delivering a shared agenda for the UK’, it explored how to ensure NHS patients benefit from the latest medicines and vaccines ...

GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new ...

Board‑level appointments this month were thick and fast, with six Boards adding new faces as Chairperson, as well as several ...

A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in ...

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in the UK, after the government reduced the offer on the table to support the ...

Sanofi's Sarclisa has played second fiddle to Johnson & Johnson's Darzalex in the treatment of multiple myeloma (MM), but the company hopes a new delivery option could give it more of a leading role.

As a tech lover, I soak it all in and leave inspired about what’s next. This was the case recently when I attended Google ...